Effects of ursodeoxycholic acid in reducing recurrence of choledocholithiasis: a randomized control trial
Phase 4
- Conditions
- Recurrent CBD stones in patients who were diagnosed with CBD stones and undergone complete removal of CBD stones by endoscopic procedure.Choledocholithiasiscommon bile duct stonesUrsodeoxycholic acid
- Registration Number
- TCTR20231102009
- Lead Sponsor
- Department of Medicine, Phramongkutklao Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Enrolling by invitation
- Sex
- All
- Target Recruitment
- 34
Inclusion Criteria
1. Undergone complete removal of CBD stones by endoscopic procedure
2. Ability and willingness to give informed consent
Exclusion Criteria
1. Residual CBD stone
2. A history of hypersensitivity to UDCA
3. Current treatment with another bile acid formulation
4. Pregnant women
5. Individuals who are diagnosed with cancer
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Recurrence rate of CBD stones at 6, 12, 18 months after intervention Endoscopic ultrasonography
- Secondary Outcome Measures
Name Time Method Adverse effects of Ursodeoxycholic acid at 3, 6, 12, 18 months after intervention Patient reported outcome using a questionnaire interview